Efficacy and Safety of Anti-CD22 CAR-T Therapy in Patients With Relapsed/Refractory B-cell Malignancies: a Single-center, Open-label, Single-arm Clinical Study
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Anti-CD22-chimeric-antigen-receptor-T-cell-therapies-Wuhan-Bio-Raid-Biotechnology (Primary)
- Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Hairy cell leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
Most Recent Events
- 08 Jul 2019 New trial record